ArticleFrontiers in immunology2026
Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: SMARCA4‑deficient non‑small‑cell lung cancer (SMARCA4‑dNSCLC) is a rare, aggressive NSCLC subtype driven by SWI/SNF complex dysfunction with no standardized therapeutic strategies. Although chemoimmunotherapy represents standard first‑line therapy for driver‑negative advanced NSCLC, its real‑world efficacy in SMARCA4‑dNSCLC remains controversial. SMARCA4 loss frequently generates an immune‑desert tumor microenvironment with low PD‑L1 and sparse CD8⁺ T‑cell infiltration, potentially conferring intrinsic resistance to immune checkpoint inhibitors (ICIs). Pre‑clinical data suggest synergism between anti‑angiogenic agents and chemoimmunotherapy; however, real‑world evidence comparing chemoimmunotherapy alone versus chemoimmunotherapy plus anti‑angiogenics for SMARCA4‑dNSCLC is limited. Methods: This single‑center retrospective cohort enrolled 22 patients with immunohistochemically‑confirmed advanced SMARCA4‑dNSCLC treated from January 2021 to September 2024. Clinicopathological characteristics, treatment regimens, survival outcomes and safety data were collected. The Kaplan‑Meier method was applied to estimate progression‑free survival (PFS) and overall survival (OS). Given the small sample size, only univariate survival analysis was performed. Objective response rate (ORR) and disease control rate (DCR) were evaluated per RECIST 1.1, and treatment‑related adverse events were graded using CTCAE v4.0. This study obtained local ethics‑committee approval with informed consent waived. The last follow‑up date was September 1, 2025. Results: Most patients were elderly male smokers with high Ki‑67, frequent adrenal metastasis and low‑to‑negative PD‑L1 expression. Compared with non‑ICI‑based therapy, ICI‑containing regimens achieved significantly superior survival: median OS not reached versus 8.7 months (HR = 0.28, 95%CI:0.08‑0.98, P = 0.047), accompanied by improved PFS, ORR and DCR. Addition of anti‑angiogenic agents brought no extra survival benefit. Elevated CYFRA21‑1 and poor ECOG‑PS predicted unfavorable prognosis. Treatment‑related adverse events were generally tolerable across groups. Conclusion: Despite an immune‑suppressed tumor microenvironment, real‑world ICI‑containing chemoimmunotherapy delivers meaningful survival benefits for advanced SMARCA4‑dNSCLC, whereas additional anti‑angiogenic combination yields no further clinical advantage. Our findings should be interpreted cautiously given retrospective design and small sample size. Large‑scale multi‑center prospective studies incorporating multivariable prognostic analyses are required to validate these results and optimize individualized treatment for this rare molecular NSCLC subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.